AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00218972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity training
Study NCT00218972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation of regular exercise
Study NCT03235089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Lens
Description: Daily disposable contact lens
Study NCT03235089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)
Study NCT04113551 — intervention group
Intervention type: DRUG
Intervention: MPH (Concerta)
Description: MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
Study NCT04113551 — intervention group
Intervention type: DRUG
Intervention: MPH (Ritalin)
Description: MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
Study NCT04113551 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine (ATO)
Description: Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
Study NCT04113551 — intervention group
Intervention type: DRUG
Intervention: Guanfacine (GFC)
Description: Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
Study NCT01595555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Free Now
Description: 8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
Study NCT01363115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice fortified with Calcium and Vitamin D
Description: Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
Study NCT01363115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice without Ca or VitD
Description: Three 240 mL glasses of orange juice without Ca or VitD
Study NCT01363115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Individual and group nutritional counseling by a registered dietitian
Study NCT01363115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Individual and group nutritional counseling by a registered dietitian
Study NCT03969017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (Peg IFN)α-2b
Description: Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
Study NCT03969017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside （acid）analogue (NAs)
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
Study NCT03969017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside （acid）analogue (NAs)
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
Study NCT00751855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: 10 weekly sessions
Study NCT00751855 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: 10 weekly sessions
Study NCT00751855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
Study NCT00751855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03238924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU oxytocin nasal spray, self-administered
Study NCT00853099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00869076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Management
Description: Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
Study NCT00869076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patient was managed by their primary care physician as usual
Study NCT03238924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline nasal spray, self-administered
Study NCT03555682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study NCT01000948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
Study NCT03555682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02561221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines.
Study NCT03675984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asymmetrical stabilization exercise
Description: Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
Study NCT00345631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Compression
Description: Manual compression
Study NCT00345631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Closure Device
Description: Investigational vascular closure device
Study NCT01029041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Exercises
Description: Exercises that aim the improvement of muscular strength of arms and legs
Study NCT01029041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Exercises that aim the improvement of muscular flexibility of arms, legs and spine
Study NCT03051919 — intervention group
Intervention type: OTHER
Intervention: observation
Study NCT01252979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium-Chain Triglycerides
Description: Subjects will take supplemental MCT oil 3 times a day for 6 months
Study NCT04256252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A scheduled therapeutic regimen with low-dose rituximab was performed.
Study NCT03263767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
Study NCT01700010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol.
Study NCT03052023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dual approach laparoscopic inguinal hernioplasty
Description: after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
Study NCT03052023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPP
Description: pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
Study NCT03052023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (lichtenstein) repair
Description: inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
Study NCT03691363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-STEP
Description: Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes > MVPA at baseline with 2) HR>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR>140 (low end of MVPA). The intervention will be 6 weeks in duration.
Study NCT02146027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Milk Drink Yakult 40
Description: Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
Study NCT02146027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Milk Drink Yakult 40
Description: Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
Study NCT02146027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Milk Drink Yakult 40
Description: Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
Study NCT02146027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Milk Drink Yakult 40
Description: Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
Study NCT04161001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
Study NCT04161001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
Study NCT04161001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
Study NCT03908970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406
Description: Twice daily
Study NCT03908970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice daily
Study NCT02733965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical Consultations
Description: The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T
Study NCT02733965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Pharmaceutical Consultations
Study NCT03068208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue-mediated photodynamic therapy
Description: The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
Study NCT03517462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3Mg Tab
Description: ivermectin tablet
Study NCT01297582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
Study NCT01297582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-6950
Description: 1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
Study NCT00524615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 25 mg of spironolactone once daily or placebo for 2 months
Study NCT00524615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spironolactone
Description: 25 mg of spironolactone once daily or placebo for 2 months
Study NCT02713659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Literacy Promotion
Description: Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
Study NCT02713659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Literacy Promotion
Description: Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
Study NCT04006392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia FX-635
Description: The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
Study NCT04006392 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Laser
Description: Non-therapeutic output.
Study NCT01067469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose Bevacizumab
Description: 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
Study NCT03344042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: 10mcg sufentanil
Study NCT03646682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy with membrane peeling
Description: during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
Study NCT03646682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with membrane peeling
Description: during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
Study NCT00860912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Matrix
Description: surgical/reinforcing material
Study NCT02840045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Description: Musical stimulation during electroencephalography recording
Study NCT00860912 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collagen Matrix
Description: surgical/reinforcing material
Study NCT00951028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)
Description: 12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
Study NCT00951028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-steps adherence treatment
Description: Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
Study NCT00951028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-steps adherence treatment
Description: Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
Study NCT03263767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nuclear cells
Description: CD3+ cells if needed after transplantation
Study NCT03263767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin Injectable Product
Description: At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Study NCT01067469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Bevacizumab
Description: 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
Study NCT01067469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
Study NCT03530501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Very low calorie ketogenic diet followed by low calorie diet
Study NCT03530501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Very low calorie ketogenic diet followed by low calorie diet
Study NCT03530501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic1
Description: B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
Study NCT03530501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic2
Description: B. animalis subsp. lactis and prebiotics fiber
Study NCT02687698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
Study NCT02693379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-VIA
Description: D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment.
Study NCT01935414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko™ post-surgery for 48hrs then 4hrs/day until discharge.
Study NCT01935414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEDS post-surgery for 48hrs then 4hrs/day until discharge.
Study NCT01727414 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OROS-Methylphenidate and placebo for inattentive type pts
Description: Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
Study NCT01727414 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OROS-Methylphenidate and placebo for combined type pts
Description: Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.